CARMAN: Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance following CAR-T-cell treatment (Arm A) as compared to standard of care induction and maintenance (Arm B)

CART-Zell-Funktion an Glioblastom Primärzelllinien

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,  Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible

A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRalpha/beta and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus
Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in
Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma

CESS-R-CESS Register

Kontinuierliches vs. intermittierendes Neuromonitoring zur Reduktion der passageren Recurrenspareserate in der Schilddrüsenchirurgie – eine prospektive, randomisierte, kontrollierte, multizentrische klinische Studie (CITY-Studie)

EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL): CLL-16 STUDIE DER DCLLSG

Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien